Biocartis Goes Public on Euronext, Raising $128M

Apr 28, 2015

|

Update: The story was updated on May 19 to include information about the underwriters exercising their overallotment option, increasing the proceed amount raised from the offering.

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis went public on Monday in Belgium, raising about €115 million ($128 million) in proceeds.

The company issued 8,695,652 shares of its common stock at €11.50 per share as part of its initial public offering. Its shares list on Euronext Brussels under ticker symbol "BCART."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Same Old Error

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Own Merits

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Back to Neanderthals

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

Featured White Papers

PCR Reaction Setup and AMPure XP Application

High-throughput qPCR and RT-qPCR Workflows Enabled by Beckman Coulter Echo Acoustic Liquid Handling and NEB Luna Reagents

Automation of PCR Reaction Setup Application Using the Biomek 4000 Laboratory Automation Workstation

Expanded Droplet Digital PCR Multiplexing Capability Using Two Different Strategies

Jul

15

Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul

16

Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response.

Jul

23

Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Menu

Biocartis Goes Public on Euronext, Raising $128M

To read the full story....

Breaking News

GenMark Diagnostics Preliminary Q2 Revenues Rise 118 Percent on SARS-CoV-2 Tests

Sequencing Study Reveals Role of RIPOR2 Mutation in Adult-Onset Hearing Loss

Progenity Asks Court to Declare Non-Infringement of Natera Patents

FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Computational Tools Help Predict Efficiency, Outcomes of Base Editors

Exome Analysis of Southwestern American Indians Highlights Metabolic Disease-Linked Variants

The Scan

Same Old Error

Own Merits

Back to Neanderthals

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

Featured White Papers

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

What's Popular?

FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

CDC Combined COVID-19/Influenza Test Gets FDA Emergency Use Authorization

FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Quidel Preliminary Q2 Revenues Jump More Than 86 Percent

Yale, NBA Validating RNA Extraction-Free Saliva Test for Coronavirus

Sponsorships